Join Drs Yancy, Jessup, Lindenfeld, Saxon, and Stevenson as they discuss how similar databases can be interpreted differently. Device-based therapy is effective when selected for the right patient; but there is considerable underuse of devices, in part due to ambiguity in the guidelines.

The overall heart failure-related mortality rate in the United States has almost doubled in the past two decades. Which patients will benefit the most from the use of ICDs? Join our panel of experts, Drs Abraham, Fonarow, Francis, and Gold as they discuss the latest evidence from clinical trials.

The science behind hyponatremia: How a physiologic approach can help stabilize patients with and without heart failure. A new class of agents emerges.

Drs Eckel, Bakris, Brown, Haffner and Leahy evaluate the link between obesity and inflammation and its impact on cardiometabolic risk. Describe the interrelationship between diabetes, hypertension, and atherosclerosis as cardiometabolic risk factors. Identify lifestyle modifications and pharmacologic treatments for cardiometabolic risk reduction. They also discuss potential role of new therapies for the prevention and management of obesity.

ADHF, a double edged sword-a failing heart and failing kidneys. Relying on diuretics alone may not be the optimal approach. New therapies offer promise, but are they safe? Join Drs Greenberg, Piña, and Carson.

Congestion is often what gets heart failure patients in trouble and, in the hospital. Currently available modalities aimed at volume overload are not perfect; safety concerns over adverse effects often limit use. A new class of agents offers promise.